Treatment of adynamic bone disease in a haemodialysis patient with teriparatide

Prevalence of adynamic bone disease (ABD), characterized by low bone turnover and absence or a reduced number of osteoblasts and osteoclasts, is increasing steadily over the last years. We present a dialysis patient, with recurrent bone fractures and biopsy-proven ABD, who was treated with teriparat...

Full description

Saved in:
Bibliographic Details
Published in:Clinical kidney journal 2015-04, Vol.8 (2), p.188-190
Main Authors: Giamalis, Panagiotis, Economidou, Dominiki, Dimitriadis, Chrysostomos, Memmos, Dimitrios, Papagianni, Aikaterini, Efstratiadis, Georgios
Format: Article
Language:English
Subjects:
Contents
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prevalence of adynamic bone disease (ABD), characterized by low bone turnover and absence or a reduced number of osteoblasts and osteoclasts, is increasing steadily over the last years. We present a dialysis patient, with recurrent bone fractures and biopsy-proven ABD, who was treated with teriparatide. Nine months after initiation of treatment, iPTH plasma levels increased to 520 pg/mL and a second bone biopsy revealed high bone turnover, normal mineralization and normal bone volume. Two years later, iPTH was 250–350 pg/dL and bone metabolism parameters within normal range. The probable utility of teriparatide in the treatment of ABD in dialysis patients is discussed.
ISSN:2048-8505
2048-8513
DOI:10.1093/ckj/sfv005